View

The Study

Effect of the GLP‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial

In simple terms

This study is like a fair test where people with alcohol problems were randomly given either a real medicine (exenatide) or a fake one (placebo) to see if it changed body chemicals linked to inflammation. We can trust the results about whether the medicine worked, but we can't say alcohol caused the high inflammation—only that it's linked.

64%

Analysis score

64/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting0
Methodology87
Publication100
Statistical54
Study type (basis of the score)
Randomized Controlled Trial
Level 1b - Individual RCT
What’s the bottom line?

People with alcohol use disorder have more inflammation and different hormone levels than others. Scientists gave them a drug called exenatide, which helps with diabetes and reduces inflammation in other diseases, to see if it helps fix these body chemicals.

Where does this study sit?

Systematic Reviews & Meta-analyses

Max 100

Randomized Trials

Max 90

Cohort Studies

Max 72

Case-Control

Max 58

Cross-Sectional

Max 44

Case Reports & Series

Max 30

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
64

64 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.

Can establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1The inflammation markers are worse in people with AUD, which may increase heart disease risk.
  2. 2But the medicine didn't improve them.
  3. 3People with AUD had IL-6 at 1.56 pg/mL (vs 0.62), hsCRP at 3.30 mg/L (vs 1.34), FGF-21 at 1795 pg/mL (vs 306), and GIP at 63 pg/mL (vs 111).
  4. 4After 6 months, exenatide didn't change these levels.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Alcohol, Clinical & Experimental Research

Year

2025

Authors

Malthe E B Hviid, Lea A N Christoffersen, M. K. Klausen, T. Brodersen, O. Pedersen, S. Ostrowski, M. Larsen, M. Kongstad, M. E. Jensen, T. Vilsbøll, Anders Fink-Jensen

Open Access
1 citations
Analysis v3
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.